Pharmacogenetics in drug regulation: Promise, potential and pitfalls

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 360, Issue 1460, 2005, Pages 1617-1638

  Shah, Rashmi R ^a,b  

^a Pharmaceutical Department   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

Adverse drug reactions; Dose response; Drug interactions; Ethnic differences; Pharmacogenetics; Regulatory guidelines

Indexed keywords

DRUG; ENZYME; GENETICS; POLYMORPHISM;

DOSE RESPONSE; DRUG CONTROL; DRUG DESIGN; DRUG THERAPY; GENETIC POLYMORPHISM; GENOTYPE; LEGAL ASPECT; METHODOLOGY; PHARMACOGENETICS; PHARMACOKINETICS; REVIEW;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; DRUG THERAPY; GENOTYPE; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 31044442759     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2005.1693     Document Type: Conference Paper

References (180)

1. Aithal, G. P., Day, C. P., Leathart, J. B. & Daly, A. K. 2000 Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10, 511-518. (http://dx.doi.org/ doi:10.1097/00008571-200008000-00004.)
2. Ando, Y. et al. 2000 Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926.
3. Arias, B., Catalan, R., Gasto, C., Gutierrez, B. & Fananas, L. 2003 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J. Clin. Psychopharmacol. 23, 563-567. (http://dx.doi.org/doi:10.1097/01. jcp.0000095350.32154.73.)
4. Backman, J. T., Kyrklund, C., Neuvonen, M. & Neuvonen, P. J. 2002 Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685-691. (http://dx.doi.org/doi:10.1067/mcp.2002.128469.)
5. Bradford, L. D. 2002 CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243.
6. Bradford, L. D., Gaedigk, A. & Leeder, J. S. 1998 High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol. Bull. 34, 797-804.
7. Branch, R. A., Adedoyin, A., Frye, R. F., Wilson, J. W. & Romkes, M. 2000 In vivo modulation of CYP enzymes by quinidine and rifampin. Clin. Pharmacol. Ther. 68, 401-411. (http://dx.doi.org/doi:10.1067/mcp.2000.110561.)
8. Brosen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H. & Gram, L. F. 1993 Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolisers of sparteine. Eur. J. Clin. Pharmacol. 44, 349-355.
9. Burchell, B. 2003 Genetic variation of human UDP-glucuronosyltransferase: implications in disease and drug glucuronidation. Am. J. Pharmacogenomics 3, 37-52.
10. Caraco, Y., Tateishi, T. & Wood, A. J. 1995 Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin. Pharmacol. Ther. 58, 62-72.
11. Caraco, Y., Sheller, J. & Wood, A. J. 1999 Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. J. Pharmacol. Exp. Ther. 290, 413-422.
12. Cargill, M. et al. 1999 Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat. Genet. 22, 231-238. (http://dx.doi.org/doi:10.1038/10290.) (Erratum in: Nat Genet. 1999 23, 373).
13. Carlini, E. J., Raftogianis, R. B., Wood, T. C., Jin, F., Zheng, W., Rebbeck, T. R. & Weinshilboum, R. M. 2001 Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics 11, 57-68. (http://dx.doi.org/doi: 10.1097/00008571-200102000-00007.)
14. Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R., Stanton Jr, V. P. & Ridker, P. M. 2004 Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291, 2821-2827. (http://dx.doi.org/doi:10.1001/jama. 291.23.2821.)
15. Cho, J. Y., Yu, K. S., Jang, I. J., Yang, B. H., Shin, S. G. & Yim, D. S. 2002 Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br. J. Clin. Pharmacol. 53, 393-397. (http://dx.doi.org/doi:10.1046/j.1365-2125.2002.01366.x.)
16. Chowbay, B., Cumaraswamy, S., Cheung, Y. B., Zhou, Q. & Lee, E. J. 2003 Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13, 89-95. (http://dx.doi.org/doi:10.1097/00008571-200302000- 00005.)
17. CIOMS 2005 Pharmacogenetics: towards improving treatment with medicines. Geneva: Council for International Organizations for Medical Sciences.
18. Clark, D. W., Donnelly, E., Coulter, D. M., Roberts, R. L. & Kennedy, M. A. 2004 Linking pharmacovigilance with pharmacogenetics. Drug Saf. 27, 1171-1184.
19. Cohen, J. S. 2001 Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch. Intern. Med. 161, 957-964. (http://dx. doi.org/doi:10.1001/archinte.161.7.957.)
20. Collie-Duguid, E. S., Pritchard, S. C., Powrie, R. H., Sludden, J., Collier, D. A., Li, T. & McLeod, H. L. 1999 The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9, 37-42.
21. Colombel, J. F. et al. 2000 Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 118, 1025-1030.
22. Coughtrie, M. W., Gilissen, R. A., Shek, B., Strange, R. C., Fryer, A. A., Jones, P. W. & Bamber, D. E. 1999 Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem. J. 337, 45-49. (http://dx.doi.org/doi:10.1042/ 0264-6021:3370045.)
23. CPMP 1997 Guidance on the investigation of drug interactions (CPMP/EWP/560/95). European Medicines Agency, London. (http://www.emea.eu.int/ htms/human/ewp/ewpfin.htm.) (Accessed on 30 December 2004)
24. CPMP 1998 Guidance on pharmacokinetic studies in man (Eudra/C/87/013). The rules governing medicinal products in the European Union EudraLex. Guidelines on efficacy, vol. 3C. Luxembourg: Office for Official Publications of the European Communities pp. 99-106 (Accessed on 30 December 2004)
25. CPMP 2001 Guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98). European Medicines Agency, London. (http://www.emea.eu.int/htms/human/ewp/ewpfin.htm.) (Accessed on 30 December 2004)
26. CPMP 2002 Position paper on terminology in pharmacogenetics (EMEA/CPMP/3070/01). European Medicines Agency, London. (http://www.emea.eu.int/ pdfs/human/press/pp/307001en.pdf.) (Accessed on 30 December 2004)
27. CPMP 2003 Concept paper on pharmacogenetics 'briefing meetings'. European Medicines Agency, London. (http://www.emea.eu.int/pdfs/human/pharmacogenetics/ 444503en.pdf.) (Accessed on 30 December 2004)
28. CPMP/ICH 1995 Guidance on dose response information to support drug registration (CPMP/ICH/378/95). European Medicines Agency, London. (http://www.emea.eu.int/htms/human/ich/efficacy/ichfin.htm.) (Accessed on 30 December 2004)
29. CPMP/ICH 1998 Guidance on ethnic factors in the acceptability of foreign clinical data (CPMP/ICH/289/95). European Medicines Agency, London. (http://www.emea.eu.int/htms/human/ich/efficacy/ichfin.htm.) (Accessed on 30 December 2004)
30. Cross, J., Lee, H., Westelinck, A., Nelson, J., Grudzinskas, C. & Peck, C. 2002 Postmarketing drug dosage changes of 499 FDA-approved new molecular entities 1980-1999. Pharmacoepidemiol. Drug Saf. 11, 439-446. (http://dx.doi.org/doi:10.1002/pds.744.)
31. Curtis, L. H. et al. 2003 Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am. J. Med. 114, 135-141. (http://dx.doi.org/ doi:10.1016/S0002-9343(02)01455-9.)
32. Dahl, M. L. 2002 Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin. Pharmacokinet. 41, 453-470.
33. Dalen, P., Dahl, M. L., Ruiz, M. L., Nordin, J. & Bertilsson, L. 1998 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63, 444-452.
34. Dalen, P., Dahl, M., Andersson, K. & Bertilsson, L. 2000 Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Br. J. Clin. Pharmacol. 49, 180-184. (http://dx.doi.org/doi:10.1046/j.1365-2125.2000.00120.x.)
35. Daly, A. K. 2003 Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17, 27-41. (http://dx.doi.org/doi:10.1046/j. 1472-8206.2003.00119.x.)
36. Daly, A. K. 2004 Pharmacogenetics of the cytochromes P450. Curr. Top. Med. Chem. 4, 1733-1744.
37. Danoff, T. M. et al. 2004 A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4, 49-53. (http://dx.doi.org/doi:10.1038/sj.tpj.6500221.)
38. Dilger, K., Greiner, B., Fromm, M. F., Hofmann, U., Kroemer, H. K. & Eichelbaum, M. 1999 Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolisers of CYP2D6. Pharmacogenetics 9, 551-559.
39. Drazen, J. M. et al. 1999 Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22, 168-170. (http://dx.doi.org/doi:10.1038/9680.)
40. Drysdale, C. M., McGraw, D. W., Stack, C. B., Stephens, J. C., Judson, R. S., Nandabalan, K., Arnold, K., Ruano, G. & Liggett, S. B. 2000 Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA 97, 10483-10488. (http://dx.doi.org/doi:10.1073/pnas.97.19.10483.)
41. Durham, L. K., Webb, S. M., Milos, P. M., Clary, C. M. & Seymour, A. B. 2004 The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 174, 525-529. (http://dx.doi.org/doi:10.1007/s00213-003-1562-3.)
42. Eichelbaum, M., Spannbrucker, N., Steincke, B. & Dengler, H. J. 1979 Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 16, 183-187.
43. Eichelbaum, M., Mineshita, S., Ohnhaus, E. E. & Zekorn, C. 1986 The influence of enzyme induction on polymorphic sparteine oxidation. Br. J. Clin. Pharmacol. 22, 49-53.
44. Eichelbaum, M., Fromm, M. F. & Schwab, M. 2004 Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. 26, 180-185. (http://dx.doi.org/doi:10.1097/00007691-200404000-00017.)
45. + channels. Eur. J. Pharmacol. 410, 281-287. (http://dx.doi.org/doi:10.1016/S0014-2999(00)00821- 9.)
46. Evans, D. A. P. 1996 Therapy. In Ethnic differences in reactions to drugs and xenobiotics (ed. W. Kalow, H. W. Goedde & D. P. Agarwal), pp. 491-526. New York: Alan R Liss.
47. Evans, D. A., Manley, K. A. & McKusick, V. A. 1960 Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485-491.
48. Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R. & Smith, R. L. 1980 A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 17, 102-105.
49. FDA 1997 Guidance note on drug metabolism/drug interaction studies in the drug development process: studies in vitro. Food and Drug Administration, Rockville, MD. (http://www.fda.gov/cder/guidance/index.htm.) (Accessed on 30 December 2004)
50. FDA 2002 Label information on STRATTERA (atomoxetine hydrochloride). Food and Drug Administration, Rockville, MD. (http://www.fda.gov/cder/foi/label/ 2002/21411_strattera_lbl.pdf.) (Accessed on 30 December 2004)
51. FDA 2003 Guidance for industry pharmacogenomic data submissions. Food and Drug Administration, Rockville, MD. (http://www.fda.gov/cder/guidance/5900dft. doc.) (Accessed on 30 December 2004)
52. FDA 2004 Minutes of the Clinical Pharmacology Subcommittee (CPSC) of the Advisory Committee for Pharmaceutical Science (ACPS), 3-4 November 2004. Food and Drug Administration, Rockville, MD. (http://www.fda.gov/ohrms/dockets/ac/04/ minutes/2004-4079M1.pdf.) (Accessed on 25 January 2005)
53. Fouassier, L., Kinnman, N., Lefevre, G., Lasnier, E., Rey, C., Poupon, R., Elferink, R. P. & Housset, C. 2002 Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37, 184-191. (http://dx.doi.org/doi:10.1016/S0168-8278(02)00107-1.)
54. Furet, Y., Bechtel, Y., Le Guellec, C., Bechtel, P. R., Autret-Leca, E. & Paintaud, G. 2002 Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. Therapie 57, 427-431. (Article in French)
55. Gardiner, S. J., Begg, E. J. & Robinson, B. A. 2002 The effect of dihydropyrimidine dehydrogenase deficiency on outcomes with fluorouracil. Adv. Drug React. Toxicol. Rev. 21, 1-16.
56. Gearry, R. B., Barclay, M. L., Burt, M. J., Collett, J. A., Chapman, B. A., Roberts, R. L. & Kennedy, M. A. 2003 Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18, 395-400. (http://dx.doi.org/doi:10.1046/j.1365-2036.2003.01690.x.)
57. Goddard, K. A., Hopkins, P. J., Hall, J. M. & Witte, J. S. 2000 Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. Am. J. Hum. Genet. 66, 216-234. (http://dx.doi.org/doi:10.1086/302727.)
58. Goldstein, D. B. 2003 Pharmacogenetics in the laboratory and the clinic. N. Engl. J. Med. 348, 553-556. (http://dx.doi.org/doi:10.1056/NEJMe020173.)
59. Guillemette, C. 2003 Pharmacogenomics of human UDP- glucuronosyltransferase enzymes. Pharmacogenomics J. 3, 136-158. (http://dx.doi.org/doi:10.1038/sj.tpj.6500171.)
60. Hamelin, B. A., Bouayad, A., Methot, J., Jobin, J., Desgagnes, P., Poirier, P., Allaire, J., Dumesnil, J. & Turgeon, J. 2000 Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin. Pharmacol. Ther. 67, 466-477. (http://dx.doi.org/doi:10.1067/mcp.2000. 106464.)
61. Hartigan-Go, K., Bateman, D. N., Nyberg, G., Martensson, E. & Thomas, S. H. 1996 Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin. Pharmacol. Ther. 60, 543-553.
62. Higashi, M. K., Veenstra, D. L., Kondo, L. M., Wittkowsky, A. K., Srinouanprachanh, S. L., Farin, F. M. & Rettie, A. E. 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698. (http://dx.doi.org/doi:10.1001/jama.287. 13.1690.)
63. Hiratsuka, M. et al. 2002 Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab. Pharmacokinet. 17, 357-362.
64. Hoffmeyer, S. et al. 2000 Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97, 3473-3478. (http://dx.doi.org/doi:10.1073/pnas.050585397.)
65. Hon, Y. Y., Fessing, M. Y., Pui, C. H., Relling, M. V., Krynetski, E. Y. & Evans, W. E. 1999 Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum. Mol. Genet. 8, 371-376. (http://dx.doi.org/doi:10. 1093/hmg/8.2.371.)
66. Idle, J. R. & Smith, R. L. 1984 The debrisoquine hydroxylation gene: a gene of multiple consequences. In Proceedings of the second world conference on clinical pharmacology and therapeutics (ed. L. Lemberger & M. M. Reidenberg), pp. 148-164. Bethesda, MD: American Society for Pharmacology and Experimental Therapeutics.
67. Idle, J. R., Corchero, J. & Gonzalez, F. J. 2000 Medical implications of HGP's sequence of chromosome 22. Lancet 355, 319.
68. Ieiri, I., Takane, H. & Otsubo, K. 2004 The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin. Pharmacokinet. 43, 553-576.
69. Ingelman-Sundberg, M. 2005 Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13. (http://dx.doi.org/doi:10.1038/sj.tpj.6500285.)
70. Innocenti, F., Stadler, W. M., Iyer, L., Ramirez, J., Vokes, E. E. & Ratain, M. J. 2000 Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin. Cancer Res. 6, 3400-3405.
71. Israel, E. et al. 2000 The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 162, 75-80.
72. Itagaki, F., Homma, M., Yuzawa, K., Nishimura, M., Naito, S., Ueda, N., Ohkohchi, N. & Kohda, Y. 2004 Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J. Pharm. Pharmacol. 56, 1055-1059. (http://dx.doi.org/doi:10.1211/0022357043914.)
73. Iyer, L. et al. 2002 UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47. (http://dx.doi.org/doi:10.1038/sj.tpj.6500072.)
74. Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P. B., Possinger, K., Roots, I. & Brockmoller, J. 2002 Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J. Clin. Oncol. 20, 2805-2811. (http://dx.doi.org/doi:10.1200/JCO.2002.09.064.)
75. Kamali, F., Khan, T. I., King, B. P., Frearson, R., Kesteven, P., Wood, P., Daly, A. K. & Wynne, H. 2004 Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. 75, 204-212. (http://dx.doi.org/doi:10.1016/j.clpt.2003.10.001.)
76. Kaneko, A., Bergqvist, Y., Takechi, M., Kalkoa, M., Kaneko, O., Kobayakawa, T., Ishizaki, T. & Bjorkman, A. 1999a Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J. Infect. Dis. 179, 974-979.
77. Kaneko, A., Bergqvist, Y., Taleo, G., Kobayakawa, T., Ishizaki, T. & Bjorkman, A. 1999b Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics 9, 317-326.
78. Kaneko, A., Lum, J. K., Yaviong, L., Takahashi, N., Ishizaki, T., Bertilsson, L., Kobayakawa, T. & Bjorkman, A. 1999c High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 9, 581-590.
79. Kaye, D. M., Smirk, B., Williams, C., Jennings, G., Esler, M. & Holst, D. 2003 Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure. Pharmacogenetics 13, 379-382. (http://dx.doi.org/doi:10.1097/00008571-200307000-00002.)
80. Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J. & Goldstein, J. A. 2001 Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11, 803-808. (http://dx.doi.org/doi:10.1097/00008571-200112000-00008.)
81. Kim, R. B. 2004 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about? Clin. Pharmacol. Ther. 75, 381-385. (http://dx.doi.org/doi:10.1016/j.clpt.2004.01.004.)
82. Kim, D. K., Lim, S. W., Lee, S., Sohn, S. E., Kim, S., Hahn, C. G. & Carroll, B. J. 2000 Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11, 215-219.
83. Kim, R. B. et al. 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70, 189-199. (http://dx.doi.org/doi:10.1067/mcp.2001.117412.)
84. Kirchheiner, J. & Brockmoller, J. 2005 Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16.
85. Kirchheiner, J., Brosen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjoqvist, F., Spina, E. & Brockmoller, J. 2001 CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. 104, 173-192. (http://dx.doi.org/doi:10.1034/j.1600-0447.2001.00299.x.) (Erratum in: Acta Psychiatr Scand. 2001 104, 475).
86. Kirchheiner, J., Bertilsson, L., Bruus, H., Wolff, A., Roots, I. & Bauer, M. 2003a Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Pharmacopsychiatry 36(Suppl. 3), 235-243. (http://dx.doi.org/doi:10.1055/s-2003- 45136.)
87. Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I. & Brockmoller, J. 2003b Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 74, 186-194. (http://dx.doi.org/doi:10.1016/S0009-9236(03)00121-8.)
88. Kirchheiner, J., Meineke, I., Steinbach, N., Meisel, C., Roots, I. & Brockmoller, J. 2003c Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2. No relationship to the CYP2C9 genetic polymorphism in humans. Br. J. Clin. Pharmacol. 55, 51-61. (http://dx.doi.org/doi:10.1046/j. 1365-2125.2003.01712.x.)
89. Kirchheiner, J. et al. 2004a Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 76, 302-312. (http://dx.doi.org/doi:10. 1016/j.clpt.2004.07.002.)
90. Kirchheiner, J., Henckel, H. B., Meineke, I., Roots, I. & Brockmoller, J. 2004b Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J. Clin. Psychopharmacol. 24, 647-652. (http://dx.doi.org/doi:10.1097/01.jcp.0000145341. 30547.f0.)
91. Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M. L., Licinio, J., Roots, I. & Brockmoller, J. 2004c Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473. (http://dx.doi.org/doi:10.1038/sj.mp. 4001494.)
92. Klotz, U., Schwab, M. & Treiber, G. 2004 CYP2C19 polymorphism and proton pump inhibitors. Pharmacol. Toxicol. 95, 2-8. (http://dx.doi.org/doi:10. 1111/j.1600-0773.2004.pto950102.x.)
93. Krasucki, C. & McFarlane, F. 1996 Electrocardiograms, high-dose antipsychotic treatment and College guidelines. Psychiatr. Bull. 20, 326-330.
94. Lee, W. & Kim, R. B. 2004 Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol. 44, 137-166. (http://dx.doi.org/doi:10.1146/ annurev.pharmtox.44.101802.121856.)
95. Lee, C. R., Goldstein, J. A. & Pieper, J. A. 2002 Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12, 251-263. (http://dx.doi.org/doi:10.1097/00008571-200204000- 00010.) (Erratum in: Pharmacogenetics 2002 12, 343).
96. Li, T., Chang, C. Y., Jin, D. Y., Lin, P. J., Khvorova, A. & Stafford, D. W. 2004 Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544. (http://dx.doi.org/doi:10.1038/nature02254.)
97. Liggett, S. B., Wagoner, L. E., Craft, L. L., Hornung, R. W., Hoit, B. D., McIntosh, T. C. & Walsh, R. A. 1998 The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J. Clin. Invest. 102, 1534-1539.
98. Lin, H. J., Han, C. Y., Lin, B. K. & Hardy, S. 1994 Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 4, 125-134.
99. Llerena, A., Berecz, R., de la Rubia, A. & Dorado, P. 2002 QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J. Psychopharmacol. 16, 361-364.
100. Loebstein, R. et al. 2001 Interindividual variability in sensitivity to warfarin - Nature or nurture? Clin. Pharmacol. Ther. 70, 159-164. (http://dx.doi.org/doi:10.1067/mcp.2001.117444.)
101. Lotrich, F. E., Pollock, B. G. & Ferrell, R. E. 2003 Serotonin transporter promoter polymorphism in African Americans: allele frequencies and implications for treatment. Am. J. Pharmacogenomics 3, 145-147.
102. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. & Smith, R. L. 1977 Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586.
103. Makkar, R. R., Fromm, B. S., Steinman, R. T., Meissner, M. D. & Lehmann, M. H. 1993 Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270, 2590-2597.
104. Marcuello, E., Altes, A., Menoyo, A., Del Rio, E., Gomez-Pardo, M. & Baiget, M. 2004 UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682.
105. Martin, J. H., Begg, E. J., Kennedy, M. A., Roberts, R. & Barclay, M. L. 2001 Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? Br. J. Clin. Pharmacol. 51, 627-630. (http://dx.doi.org/doi:10.1046/ j.0306-5251.2001.01398.x.)
106. Marzolini, C., Paus, E., Buclin, T. & Kim, R. B. 2004a Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75, 13-33. (http://dx.doi.org/doi:10.1016/j.clpt.2003.09.012.)
107. Marzolini, C., Tirona, R. G. & Kim, R. B. 2004b Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5, 273-282. (http://dx.doi.org/doi: 10.1517/phgs.5.3.273.29831.)
108. Meyer, U. A. 2000 Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671. (http://dx.doi.org/doi:10.1016/S0140-6736(00)03167-6.)
109. MHLW 2001a Guidance on clinical pharmacokinetic studies of pharmaceuticals, ELD Notification No 796, Ministry of Health, Labour and Welfare, Tokyo, Japan.
110. MHLW 2001b Guidance on methods of drug interaction studies, ELD Notification No 813, Ministry of Health, Labour and Welfare, Tokyo, Japan.
111. Mizutani, T. 2003 PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 35, 99-106. (http://dx.doi.org/doi:10.1081/DMR-120023681.)
112. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S. & Abe, T. 2004 The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet. 19, 171-179. (http://dx.doi.org/doi:10.2133/dmpk.19.171.)
113. Morgan, M. Y., Reshef, R., Shah, R. R., Oates, N. S., Smith, R. L. & Sherlock, S. 1984 Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25, 1057-1064.
114. Morike, K. E. & Roden, D. M. 1994 Quinidine-enhanced beta-blockade during treatment with propafenone in extensive metabolizer human subjects. Clin. Pharmacol. Ther. 55, 28-34.
115. Murata, M., Tamai, I., Sai, Y., Nagata, O., Kato, H., Sugiyama, Y. & Tsuji, A. 1998 Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metab. Dispos. 26, 1113-1119.
116. Murphy, M. P. 2000 Current pharmacogenomic approaches to clinical drug development. Pharmacogenomics 1, 115-123.
117. Murphy, M. P., Beaman, M. E., Clark, L. S., Cayouette, M., Benson, L., Morris, D. M. & Polli, J. W. 2000 Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. Pharmacogenetics 10, 583-590. (http://dx.doi.org/doi:10.1097/00008571-200010000- 00002.)
118. Murphy Jr, G. M., Kremer, C., Rodrigues, H. E. & Schatzberg, A. F. 2003 Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry 160, 1830-1835. (http://dx.doi.org/doi:10.1176/appi.ajp.)
119. Nebert, D. W. 2000 Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 10, 279-290. (http://dx.doi.org/doi:10.1097/00008571-200006000- 00001.)
120. Nebert, D. W., Jorge-Nebert, L. & Vesell, E. S. 2003 Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements. Am. J. Pharmacogenomics 3, 361-370.
121. Ng, M. C., Wang, Y., So, W. Y., Cheng, S., Visvikis, S., Zee, R. Y., Fernandez-Cruz, A., Lindpaintner, K. & Chan, J. C. 2004 Ethnic differences in the linkage disequilibrium and distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular diseases. Genomics 83, 559-565. (http://dx.doi.org/doi:10.1016/j.ygeno.2003.09.008.)
122. Oldenburg, J. et al. 2000 Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb. Haemost. 84, 937-941.
123. Ozawa, S. et al. 2004 Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab. Pharmacokinet. 19, 83-95. (http://dx.doi.org/doi:10.2133/dmpk.19.83.)
124. Parker, R. B., Yates, C. R., Soberman, J. E. & Laizure, S. C. 2003 Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 23, 979-987. (http://dx.doi.org/doi:10.1592/ phco.23.8.979.32881.)
125. Perlis, R. H., Mischoulon, D., Smoller, J. W., Wan, Y. J., Lamon-Fava, S., Lin, K. M., Rosenbaum, J. F. & Fava, M. 2003 Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 54, 879-883. (http://dx.doi.org/doi:10.1016/S0006-3223(03)00424-4.)
126. Peyvandi, F., Spreafico, M., Siboni, S. M., Moia, M. & Mannucci, P. M. 2004 CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther. 75, 198-203. (http://dx.doi.org/doi:10.1016/j.clpt.2003.09.015.)
127. Pollock, B. G. et al. 2000 Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23, 587-590. (http://dx.doi.org/doi:10.1016/ S0893-133X(00)00132-9.)
128. Priori, S. G., Napolitano, C. & Schwartz, P. J. 1999 Low penetrance in the long-QT syndrome: clinical impact. Circulation 99, 529-533.
129. Ramirez, J., Iyer, L., Journault, K., Belanger, P., Innocenti, F., Ratain, M. J. & Guillemette, C. 2002 In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm. Res. 19, 588-594. (http://dx.doi.org/doi:10.1023/A: 1015341726183.)
130. Raschetti, R., Maggini, M., Da Cas, R., Popoli, P. & Rossi, A. 2001 Time trends in the coprescribing of cisapride and contraindicated drugs in Umbria, Italy. JAMA 285, 1840-1841. (http://dx.doi.org/doi:10.1001/jama.285.14. 1840.)
131. Rau, T., Wohlleben, G., Wuttke, H., Thuerauf, N., Lunkenheimer, J., Lanczik, M. & Eschenhagen, T. 2004 CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin. Pharmacol. Ther. 75, 386-393. (http://dx.doi.org/doi:10.1016/j.clpt.2003. 12.015.)
132. Regueiro, M. & Mardini, H. 2002 Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease. J. Clin. Gastroenterol. 35, 240-244. (http://dx.doi.org/doi:10.1097/00004836-200209000-00008.)
133. Roe, C. M., Odell, K. W. & Henderson, R. R. 2003 Concomitant use of antipsychotics and drugs that may prolong the QT interval. J. Clin. Psychopharmacol. 23, 197-200. (http://dx.doi.org/doi:10.1097/00004714-200304000- 00013.)
134. Rost, S. et al. 2004 Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541. (http://dx.doi.org/doi:10.1038/nature02214.)
135. Rouits, E., Boisdron-Celle, M., Dumont, A., Guerin, O., Morel, A. & Gamelin, E. 2004 Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159.
136. Saarinen, K., Swan, H., Kainulainen, K., Toivonen, L., Viitasalo, M. & Kontula, K. 1998 Molecular genetics of the long QT syndrome: two novel mutations of the KVLQT1 gene and phenotypic expression of the mutant gene in a large kindred. Hum. Mutat. 11, 158-165.
137. Sagar, M., Janczewska, I., Ljungdahl, A., Bertilsson, L. & Seensalu, R. 1999 Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment. Aliment. Pharmacol. Ther. 13, 453-458. (http://dx.doi.org/doi:10.1046/j.1365-2036.1999.00490.x.)
138. Sallustio, B. C., Westley, I. S. & Morris, R. G. 2002 Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br. J. Clin. Pharmacol. 54, 107-114. (http://dx.doi.org/doi:10.1046/j.1365-2125.2002.01618.x.)
139. Schaeffeler, E., Fischer, C., Brockmeier, D., Wernet, D., Moerike, K., Eichelbaum, M., Zanger, U. M. & Schwab, M. 2004 Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 14, 407-417. (http://dx.doi.org/doi:10.1097/01.fpc.0000114745.
140. Schwab, M. et al. 2002 Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 12, 429-436. (http://dx.doi.org/doi:10.1097/00008571-200208000-00003.)
141. Schwartz, G. L. & Turner, S. T. 2004 Pharmacogenetics of antihypertensive drug responses. Am. J. Pharmacogenomics 4, 151-160.
142. Scordo, M. G., Aklillu, E., Yasar, U., Dahl, M. L., Spina, E. & Ingelman-Sundberg, M. 2001 Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52, 447-450. (http://dx.doi.org/doi:10.1046/j.0306-5251.2001.01460.x.)
143. Shah, R. R. 1999 Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adverse Drug React. Toxicol Rev. 18, 181-233.
144. Shah, R. R. 2002 The significance of QT interval in drug development. Br. J. Clin. Pharmacol. 54, 188-202. (http://dx.doi.org/doi:10.1046/j.1365-2125. 2002.01627.x.)
145. Shah, R. R. 2004 Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Drug Saf. 27, 145-172.
146. Shah, R. R., Oates, N. S., Idle, J. R., Smith, R. L. & Lockhart, J. D. 1982 Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br. Med. J. 1, 295-299.
147. Shaw, P. 2002 Pharmacogenetic applications in clinical development. International Clinical Trials Symposium, Sydney, Australia, 21-23 October.
148. Shimizu, T. et al. 2003 Bioinformatics research on inter-racial difference in drug metabolism. I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab. Pharmacokinet. 18, 48-70.
149. Smalley, W. et al. 2000 Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 284, 3036-3039. (http://dx.doi.org/doi.-10.1001/jama.284.23.3036.)
150. Soranzo, N., Cavalleri, G. L., Weale, M. E., Wood, N. W., Depondt, C., Marguerie, R., Sisodiya, S. M. & Goldstein, D. B. 2004 Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res. 14, 1333-1344. (http://dx.doi.org/doi:10.1101/gr. 1965304.)
151. Stephens, J. C. et al. 2001 Haplotype variation and linkage disequilibrium in 313 human genes. Science 293, 489-493. (http://dx.doi.org/doi: 10.1126/science.1059431.) (Erratum in: Science 2001 293, 1048)
152. Sunahara, S., Urano, M. & Ogawa, M. 1961 Genetical and geographic studies on isoniazid inactivation. Science 134, 1530-1531.
153. Suzuki, Y., Shioiri, T., Muratake, T., Kawashima, Y., Sato, S., Hagiwara, M., Inoue, Y., Shimoda, K. & Someya, T. 2003 Effects of concomitant fluvoxamine on the metabolism of alprazolam in Japanese psychiatric patients: interaction with CYP2C19 mutated alleles. Eur. J. Clin. Pharmacol. 58, 829-833.
154. Takahashi, H., Wilkinson, G. R., Caraco, Y., Muszkat, M., Kim, R. B., Kashima, T., Kimura, S. & Echizen, H. 2003 Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther. 73, 253-263. (http://dx.doi.org/doi:10.1067/ mcp.2003.26a.)
155. Takahashi, H., Ieiri, I., Wilkinson, G. R., Mayo, G., Kashima, T., Kimura, S., Otsubo, K. & Echizen, H. 2004 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 103, 3055-3057. (http://dx.doi.org/doi:10.1182/ blood-2003-07-2521.)
156. Thanaccody, R., Daly, A. K. & Thomas, S. H. 2003 Influence of CYP2D6 genotype on the QTc interval and plasma concentrations of thioridazine and its metabolites in psychiatric patients taking chronic therapy. Clin. Pharmacol. Ther. 73, 77.
157. Tirona, R. G. & Kim, R. B. 2002 Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv. Drug Deliv. Rev. 54, 1343-1352. (http://dx.doi.org/doi:10.1016/S0169-409X(02)00077-7.)
158. Tirona, R. G., Leake, B. F., Merino, G. & Kim, R. B. 2001 Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669-35675. (http://dx.doi.org/doi:10.1074/jbc.M103792200.)
159. Tremblay, P. B., Kaiser, R., Sezer, O., Rosler, N., Schelenz, C., Possinger, K., Roots, I. & Brockmoller, J. 2003 Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J. Clin. Oncol. 21, 2147-2155. (http://dx.doi.org/doi:10.1200/JCO.2003.05.164.)
160. Tucker, G. 2004 Pharmacogenetics - expectations and reality. Br. Med. J. 329, 4-6.
161. Turgeon, J., Pavlou, H. N., Wong, W., Funck-Brentano, C. & Roden, D. M. 1990 Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J. Pharmacol. Exp. Ther. 255, 642-649.
162. Turgeon, J. et al. 1991 Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man. J. Pharmacol. Exp. Ther. 259, 789-798.
163. van Aken, J., Schmedders, M., Feuerstein, G. & Kollek, R. 2003 Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am. J. Pharmacogenomics 3, 149-155.
164. van der Weide, J., Steijns, L. S., van Weelden, M. J. & de Haan, K. 2001 The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 11, 287-291. (http://dx.doi.org/doi:10.1097/ 00008571-200106000-00002.)
165. Verstuyft, C., Robert, A., Morin, S., Loriot, M. A., Flahault, A., Beaune, P., Funck-Brentano, C., Jaillon, P. & Becquemont, L. 2003 Genetic and environmental risk factors for oral anticoagulant overdose. Eur. J. Clin. Pharmacol. 58, 739-745.
166. Vincent, G. M., Timothy, K. W., Leppert, M. & Keating, M. 1992 The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N. Engl. J. Med. 327, 846-852.
167. Wadelius, M., Darj, E., Frenne, G. & Rane, A. 1997 Induction of CYP2D6 in pregnancy. Clin. Pharmacol. Ther. 62, 400-407.
168. Wang, J. S., Neuvonen, M., Wen, X., Backman, J. T. & Neuvonen, P. J. 2002 Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 30, 1352-1356. (http://dx.doi.org/doi:10.1124/ dmd.30.12.1352.)
169. Wang, L. S. et al. 2004 St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin. Pharmacol. Ther. 75, 191-197. (http://dx.doi.org/doi:10.1016/j.clpt.2003. 09.014.)
170. Watanabe, I. et al. 2003 A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 73, 435-455. (http://dx.doi.org/doi:10.1016/S0009-9236(03)00014-6.)
171. Wedlund, P. J. & de Leon, J. 2004 Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence? Clin. Pharmacol. Ther. 75, 373-375. (http://dx.doi.org/doi:10.1016/j.clpt.2004.01.002.)
172. Weinshilboum, R. M. 1984 Human pharmacogenetics of methyl conjugation. Fed. Proc. 43, 2303-2307.
173. Weir, T. D. et al. 1998 Beta2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am. J. Respir. Crit. Care Med. 158, 787-791.
174. Weizman, A. & Weizman, R. 2000 Serotonin transporter polymorphism and response to SSRIs in major depression and relevance to anxiety disorders and substance abuse. Pharmacogenomics 1, 335-341.
175. Wysowski, D. K., Corken, A., Gallo-Torres, H., Talarico, L. & Rodriguez, E. M. 2001 Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions. Am. J. Gastroenterol. 96, 1698-1703. (doi:dx. doi.org/doi:10.1016/S0002-9270(01)02490-X.)
176. Xie, H. G., Kim, R. B., Wood, A. J. & Stein, C. M. 2001 Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850. (http://dx.doi.org/doi:10.1146/annurev. pharmtox.41.1.815.)
177. Xie, H. G., Prasad, H. C., Kim, R. B. & Stein, C. M. 2002 CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270. (http://dx.doi.org/doi:10.1016/S0169-409X(02)00076-5. )
178. Yasui-Furukori, N., Saito, M., Uno, T., Takahata, T., Sugawara, K. & Tateishi, T. 2004a Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J. Clin. Pharmacol. 44, 1223-1229. (http://dx.doi.org/doi:10.1177/0091270004269015.)
179. Yasui-Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., Inoue, Y., Kaneko, S. & Tateishi, T. 2004b Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br. J. Clin. Pharmacol. 57, 487-494. (http://dx.doi.org/doi:10.1111/j.1365-2125.2003.02047.x.)
180. Zhang, L., Dresser, M. J., Gray, A. T., Yost, S. C., Terashita, S. & Giacomini, K. M. 1997 Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51, 913-921.